相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Single-Unit Umbilical Cord Blood Transplantation from Unrelated Donors in Adult Patients with Chronic Myelogenous Leukemia
Jaime Sanz et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV
Susanne Saussele et al.
BLOOD (2010)
Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase
Jiri Pavlu et al.
BLOOD (2010)
Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the chronic leukemia working party of the EBMT
Y. Chalandon et al.
BONE MARROW TRANSPLANTATION (2010)
Maintenance Therapy With Low-Dose Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for Recurrent Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Marcos de Lima et al.
CANCER (2010)
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Dragana Milojkovic et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Relapse and Late Mortality in 5-Year Survivors of Myeloablative Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia in First Chronic Phase
John M. Goldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Standardisation of molecular monitoring for chronic myeloid leukaemia
Nicholas C. P. Cross
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2009)
The blast phase of chronic myeloid leukaemia
Richard T. Silver
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2009)
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up
Ravin J. Garg et al.
BLOOD (2009)
Risk Score for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation A Retrospective Analysis
Alois Gratwohl et al.
CANCER (2009)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sustained major molecular response in the absence of any antileukaemic therapy after dasatinib treatment and autologous peripheral blood stem cell transplantation in a patient with imatinib-resistant myeloblastic-phase chronic myeloid leukaemia
D. Rea et al.
LEUKEMIA (2009)
Can we include vaccines with stem-cell transplantation?
John Barrett et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
Stephanie J. Lee et al.
BLOOD (2008)
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
Constantine S. Tam et al.
BLOOD (2008)
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
David Marin et al.
BLOOD (2008)
Unrelated cord blood transplantation in CML: Japan Cord Blood Bank Network analysis
T. Nagamura-Inoue et al.
BONE MARROW TRANSPLANTATION (2008)
Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis
Hugues de Lavallade et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy
A. S. M. Yong et al.
LEUKEMIA (2008)
Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia
Eduardo Olavarria et al.
BLOOD (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
Mhairi Copland et al.
BLOOD (2006)
Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy
Jaspal Kaeda et al.
BLOOD (2006)
Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation
BN Savani et al.
BONE MARROW TRANSPLANTATION (2005)
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT
C Crawley et al.
BLOOD (2005)
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
ML Sorror et al.
BLOOD (2005)
Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants
JR Passweg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs
SJ Lee et al.
BLOOD (2002)
Current trends in hematopoietic stem cell transplantation in Europe
A Gratwohl et al.
BLOOD (2002)
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
SM Graham et al.
BLOOD (2002)
Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors
SM Davies et al.
AMERICAN JOURNAL OF MEDICINE (2001)
Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia
E Olavarria et al.
BLOOD (2001)
Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis
C Craddock et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
The story of chronic myeloid leukaemia
CG Geary
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia
G Visani et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
JJ Molldrem et al.
NATURE MEDICINE (2000)
分享论文
